Full video transcriptClick to expand
Auto-generated transcript of @beautybyjorge's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I think I'm gaining some weight.
- 0:05I think I'm gaining some weight.
- 0:10It's not that bad.
Stopping Ozempic: what actually happens when you quit semaglutide
Quick answer
The creator reports noticeable weight gain after discontinuing semaglutide (Ozempic), which is consistent with the pharmacological profile of GLP-1 receptor agonists: appetite suppression and metabolic effects are tied to active drug presence and largely reverse upon discontinuation. Clinical trial data indicates most patients regain a substantial portion of lost weight within one year of stopping. The creator's characterization of regain as mild is plausible for their individual case but should not be generalized, particularly for patients with obesity-related comorbidities.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Stopping Ozempic: what actually happens when you quit semaglutide, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Stopping Ozempic: what actually happens when you quit semaglutide" from BeautybyJorge. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports noticeable weight gain after discontinuing semaglutide (Ozempic), which is consistent with the pharmacological profile of GLP-1 receptor agonists: appetite suppression and metabolic effects are tied to active drug presence and largely reverse upon discontinuation.
The reason this review is not generic is the source wording and the canonical claim label "glp1 ya dej de usar el ozempic y vamos para arriba." In this clip, the useful excerpt is: "I think I'm gaining some weight." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator reports noticeable weight gain after discontinuing semaglutide (Ozempic), which is consistent with the pharmacological profile of GLP-1 receptor agonists: appetite suppression and metabolic effects are tied to active drug presence and largely reverse upon discontinuation.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator reports noticeable weight gain after discontinuing semaglutide (Ozempic), which is consistent with the pharmacological profile of GLP-1 receptor agonists: appetite suppression and metabolic effects are tied to active drug presence and largely reverse upon discontinuation. Clinical trial data indicates most patients regain a substantial portion of lost weight within one year of stopping. The creator's characterization of regain as mild is plausible for their individual case but should not be generalized, particularly for patients with obesity-related comorbidities.
- Wilding et al. (2022, Diabetes, Obesity and Metabolism): participants regained roughly two-thirds of their total semaglutide-related weight loss within 12 months of stopping the drug.
- Cardiovascular risk markers including blood pressure and lipids also worsened back toward baseline after discontinuation in the STEP 1 extension trial.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Wilding et al. (2022, Diabetes, Obesity and Metabolism): participants regained roughly two-thirds of their total semaglutide-related weight loss within 12 months of stopping the drug.
- Cardiovascular risk markers including blood pressure and lipids also worsened back toward baseline after discontinuation in the STEP 1 extension trial.
- Rubino et al. (2023, Obesity): the body does not retain a lower weight set point after stopping GLP-1 therapy. Hunger hormone signaling resumes its pre-treatment pattern.
- Aronne et al. (2024, JAMA, SURMOUNT-4): patients who continued tirzepatide after an initial treatment phase maintained significantly more weight loss than those who switched to placebo, supporting long-term use models.
- Post-GLP-1 regain is not a personal failure. It reflects the drug's mechanism, not a patient's behavior during treatment.
- If stopping due to cost or access, a clinician may have options including dose reduction or transition planning that could reduce the pace of regain.
- "Not that bad" regain varies widely depending on how much was lost and over what period. For patients with significant obesity-related disease, even partial regain can have meaningful health consequences.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @beautybyjorge actually say?
Pretty much exactly what the research predicts. The creator says "I think I'm gaining some weight" after stopping Ozempic, then adds "it's not that bad." That's it. No dramatic claims, no miracle cure narrative, no dangerous advice. Just a personal observation about what happens when you stop a GLP-1 medication. Credit where it's due: this is one of the more honest GLP-1 posts circulating on TikTok right now.
The caption, translated from Spanish, says they stopped using Ozempic and are "going up" (gaining weight), with laughing emojis. The tone is self-aware, not alarmist. But 22,900 viewers are watching this, and the implied takeaway, that post-GLP-1 weight regain is somehow mild or no big deal, deserves a closer look at what the actual data says.
Does the science back this up?
Yes, the basic fact checks out. Weight regain after stopping semaglutide is well-documented and consistent. The question is how much, and how fast.
The STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants for one year after stopping semaglutide 2.4 mg. On average, they regained two-thirds of the weight they had lost within 12 months. Cardiovascular risk markers also worsened back toward baseline. This wasn't a fringe result. It aligned with what researchers had already seen with liraglutide discontinuation in earlier trials.
A 2023 analysis by Rubino et al. in Obesity confirmed that GLP-1 receptor agonists suppress appetite partly through central nervous system pathways that return to baseline signaling once the drug is cleared. The body doesn't "learn" a new weight set point from the drug. It resumes the hormonal environment that existed before treatment.
What did they get wrong (or right)?
They got the direction right: stopping Ozempic causes weight to go up. But "it's not that bad" is where this gets complicated, and potentially misleading for viewers in different situations.
For someone who lost 10 pounds on semaglutide and has now regained two or three pounds, sure, that might genuinely feel manageable. But for someone who lost 40 or 50 pounds and stops the medication, the Wilding 2022 data suggests they could regain 25 to 35 pounds within a year. That's not a small thing metabolically or psychologically.
The creator isn't wrong about their own experience. The problem is that personal anecdote framed as reassurance can quietly communicate to viewers that discontinuation is low-stakes. For people managing type 2 diabetes, cardiovascular disease, or severe obesity, it often isn't. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that continued tirzepatide use after an initial loss phase produced significantly better weight maintenance than placebo, reinforcing that these medications often need to be ongoing, not temporary.
What should you actually know?
GLP-1 receptor agonists like semaglutide work while you take them. That's not a flaw in the drug. It's just how the mechanism works, and stopping without a plan is where things go sideways for a lot of patients.
Here's what the evidence actually supports:
- Most people regain a significant portion of lost weight within 6-12 months of stopping (Wilding et al., 2022).
- The regain isn't because patients "failed." It reflects the drug's role in suppressing hunger hormones, including ghrelin, and slowing gastric emptying. Remove the drug, those signals return.
- Some patients do maintain partial weight loss after stopping, particularly those who made durable changes to eating patterns during treatment. But this is not the majority outcome in clinical trials.
- If you're stopping because of cost, side effects, or access issues, talking to a clinician before stopping matters. There may be dose-adjustment options or transition strategies worth knowing about.
The creator's lightness about this is understandable, and their experience may genuinely be mild so far. But the framing should not be the default assumption for anyone else making this decision.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
BeautybyJorge · TikTok creator
22.9K views on this video
Ya dejé de usar el ozempic…. Y vamos para arriba… 😂😂😂❤️❤️❤️
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about wilding et al. (2022, diabetes, obesity?
Wilding et al. (2022, Diabetes, Obesity and Metabolism): participants regained roughly two-thirds of their total semaglutide-related weight loss within 12 months of stopping the drug.
What does the video say about cardiovascular risk markers including blood pressure?
Cardiovascular risk markers including blood pressure and lipids also worsened back toward baseline after discontinuation in the STEP 1 extension trial.
What does the video say about rubino et al. (2023, obesity): the body does not retain?
Rubino et al. (2023, Obesity): the body does not retain a lower weight set point after stopping GLP-1 therapy. Hunger hormone signaling resumes its pre-treatment pattern.
What does the video say about aronne et al. (2024, jama, surmount-4): patients who continued tirzepatide?
Aronne et al. (2024, JAMA, SURMOUNT-4): patients who continued tirzepatide after an initial treatment phase maintained significantly more weight loss than those who switched to placebo, supporting long-term use models.
What does the video say about post-glp-1 regain?
Post-GLP-1 regain is not a personal failure. It reflects the drug's mechanism, not a patient's behavior during treatment.
What does the video say about if stopping due to cost?
If stopping due to cost or access, a clinician may have options including dose reduction or transition planning that could reduce the pace of regain.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by BeautybyJorge, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.